SCHEMBL7094919

SCHEMBL7094919

C=C(C)CCNc1nc(Cl)nc2c1ncn2C(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.60
CDK5 Q00535 13/20 0.53
CDK5R1 Q15078 12/20 0.53
CDK2 P24941 10/20 0.53
CCNA2 P20248 9/20 0.53
CCNA1 P78396 9/20 0.53
DYRK1A Q13627 8/20 0.53
NPC1 O15118 2/20 0.51
POLB P06746 1/20 0.51
PRKACA P17612 1/20 0.48
PRKACG P22612 1/20 0.48
PRKACB P22694 1/20 0.48
MAPK3 P27361 1/20 0.48
MAPK1 P28482 1/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC8 Q9BY41 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285480 0.83 CDK2 (0.66) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL6817833 0.81 CDK1 (0.63) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL24966176 0.81 CDK1 (0.69) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL2318905 0.78 CDK1 (0.62) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL17628610 0.78 CDK1 (0.79) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL22131204 0.76 CDK5 (0.65) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL6821041 0.76 CDK1 (0.62) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL5196519 0.75 CDK1 (0.55) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL6152647 0.75 CDK1 (0.82) CDK1CDK5CDK5R1CDK2CCNA2
SCHEMBL1400442 0.75 CDK1 (1.00) CDK1CDK5CDK2DYRK1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2003-10-02 US claimed
EP-1308447-A1 Purine derivatives having antiproliferative properties and biological uses thereof Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2003-05-07 EP claimed
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2002-04-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK5 517/4885CDK5R1 881/4885
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK5 517/4885CDK5R1 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.